Announcement of patent registration in Korea for Redosemtide’s use in cartilage diseases

Overview

This news brief communicates the expectation that Korea-wide patent registration for Redosemtide is likely to be determined. The patent covers uses as a therapeutic for cartilage diseases (traumatic cartilage defects, osteoarthritis, osteochondritis dissecans), with StemRIM Co., Ltd. and Osaka University as applicants. The expansion of Redosemtide’s indications is under consideration, and completion of registration is expected to secure development potential in the Korean market.

Impact on shareholders and outlook

The patent registration does not specify any direct financial impact, and there is no effect on the full-year results for the fiscal year ending July 2027. Future disclosures may be issued as the patent registration progresses or new indications are developed.